Evidence map›Paper›PMID 35967396›Full record

ArticleFrontiers in immunology2022

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.

Andrea Kosta, Abdelilah Mekhloufi, Lorenzo Lucantonio, Alessandra Zingoni, Alessandra Soriani, Marco Cippitelli, Angela Gismondi, Francesca Fazio, Maria Teresa Petrucci, Angela Santoni and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. The Role of TAM Receptors in Bone.International journal of molecular sciences · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Andrea KostaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Abdelilah MekhloufiDepartment of Biomedical Engineering, Emory University, Atlanta, GA, United States.
Lorenzo LucantonioDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra ZingoniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra SorianiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Marco CippitelliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Angela GismondiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Francesca FazioDivision of Hematology, Department of Translational Medicine and Precision, Sapienza University of Rome, Rome, Italy.
Maria Teresa PetrucciDivision of Hematology, Department of Translational Medicine and Precision, Sapienza University of Rome, Rome, Italy.
Angela SantoniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Helena StabileDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Cinzia FiondaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NKG2D ligands play a relevant role in Natural Killer (NK) cell -mediated immune surveillance of multiple myeloma (MM). Different levels of regulation control the expression of these molecules at cell surface. A number of oncogenic proteins and miRNAs act as negative regulators of NKG2D ligand transcription and translation, but the molecular mechanisms sustaining their basal expression in MM cells remain poorly understood. Here, we evaluated the role of the growth arrest specific 6 (GAS6)/TAM signaling pathway in the regulation of NKG2D ligand expression and MM recognition by NK cells. Our data showed that GAS6 as well as MERTK and AXL depletion in MM cells results in MICA downregulation and inhibition of NKG2D-mediated NK cell degranulation. Noteworthy, GAS6 derived from bone marrow stromal cells (BMSCs) also increases MICA expression at both protein and mRNA level in human MM cell lines and in primary malignant plasma cells. NF-kB activation is required for these regulatory mechanisms since deletion of a site responsive for this transcription factor compromises the induction of

Indexed as

Histocompatibility Antigens Class IIntercellular Signaling Peptides and ProteinsMultiple MyelomaNK Cell Lectin-Like Receptor Subfamily KGrowth Arrest-Specific Protein 6HumansLigandsNF-kappa BSignal TransductionGrowth Arrest-Specific Protein 6Histocompatibility Antigens Class IIntercellular Signaling Peptides and ProteinsKLRK1 protein, humanLigandsMHC class I-related chain ANF-kappa BNK Cell Lectin-Like Receptor Subfamily KAXLbone marrow stromal cellsGAS6MERTKMICAmultiple myelomanatural killer cellsNKG2D ligand

Identifiers

PMID35967396
PMCPMC9368199
OpenAlexW4288096020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.